Literature DB >> 30240679

Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis.

Steven M Smith1, Rhonda M Cooper-DeHoff2.   

Abstract

The US Food and Drug Administration recently granted an approved indication for the first fixed-dose combination antihypertensive (amlodipine) and nonsteroidal anti-inflammatory drug (celecoxib) for treatment of comorbid hypertension and osteoarthritis. This review summarizes available data on this combination product, to be marketed as Consensi (Kitov Pharmaceuticals, Ltd, Tel Aviv, Israel), and discusses its potential place in therapy.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Amlodipine; Amlodipine/celecoxib; Celecoxib; Consensi; Fixed-dose combination; Hypertension; KIT-302; Osteoarthritis

Mesh：

Substances：

Year:  2018        PMID： 30240679     DOI： 10.1016/j.amjmed.2018.08.027

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


  4 in total

Review 1.  Innovative highlights of clinical drug trial design.

Authors:  Daohong Chen; Eric Yining Qi
Journal:  Transl Res       Date:  2020-06-03       Impact factor: 7.012

2.  Effects of Different Nonsteroidal Anti-Inflammatory Drugs Combined with Platelet-Rich Plasma on Inflammatory Factor Levels in Patients with Osteoarthritis.

Authors:  Wenxiao Jiang; Yijun Zhang; Ye Huang; Yunfeng Cheng
Journal:  J Healthc Eng       Date:  2022-03-31       Impact factor: 2.682

3.  Development of UV spectrophotometry methods for concurrent quantification of amlodipine and celecoxib by manipulation of ratio spectra in pure and pharmaceutical formulation.

Authors:  Mahesh Attimarad; Venugopla Katarigatta Narayanswamy; Bandar Essa Aldhubaib; Nagaraja SreeHarsha; Anroop Balachandran Nair
Journal:  PLoS One       Date:  2019-09-16       Impact factor: 3.240

4.  Exploiting Curcumin Synergy With Natural Products Using Quantitative Analysis of Dose-Effect Relationships in an Experimental In Vitro Model of Osteoarthritis.

Authors:  Angela D'Ascola; Natasha Irrera; Roberta Ettari; Alessandra Bitto; Giovanni Pallio; Federica Mannino; Marco Atteritano; Giuseppe M Campo; Letteria Minutoli; Vincenzo Arcoraci; Violetta Squadrito; Giacomo Picciolo; Francesco Squadrito; Domenica Altavilla
Journal:  Front Pharmacol       Date:  2019-11-14       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.